December 2019 FDA Recall Memantine Hydrochloride by Lupin Pharmaceuticals Inc.
D-0629-2020 - Failed Dissolution Specifications

This Class III drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on December 10, 2019 for the product Memantine Hydrochloride. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0629-2020

Reason for Recall
Failed Dissolution Specifications: High out of specification result observed at stability studies.
Initiated
12-10-2019
Reported
12-25-2019
Quantity
3,726 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Lupin Pharmaceuticals Inc.
Nationwide in the USA
Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in a) 90-count bottles (NDC 68180-249-09 and b) 500-count bottles (NDC 68180-249-02); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, INDIA

Batch or Lot Expiration Information

Lot# : H901787, H901788, Exp March 2021